Overview

Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis

Status:
Completed
Trial end date:
2019-04-22
Target enrollment:
Participant gender:
Summary
Phase 3 study to evaluate the safety and efficacy of treatment with RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.
Phase:
Phase 3
Details
Lead Sponsor:
RevitaLid Inc.
RVL Pharmaceuticals, Inc.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions